MannKind shares surge after U.S. regulators expand Afrezza’s use to children with diabetes, broadening its market potential.
MannKind Corporation (MNKD) received U.S. Food and Drug Administration approval to expand its inhaled insulin therapy, Afrezza, for use in children with diabetes. The decision allows the inhalation powder, developed using MannKind’s Technosphere drug-delivery technology, to target a younger patient population previously unserved by the product.
Prior to the approval, Afrezza was limited to adults with diabetes. The expansion follows the company’s request to address pediatric needs, potentially increasing its addressable market. Analysts had anticipated the move, though no specific revenue projections were disclosed.
Shares of MNKD rose sharply following the announcement, reflecting investor optimism about the therapy’s growth prospects.